Mutated Ras-transfected, EBV-transformed lymphoblastoid cell lines as a model tumor vaccine for boosting T-cell responses against pancreatic cancer: A pilot trial

Human Gene Therapy

Volumn 23, Issue 12, 2012, Pages 1224-1236

  Kubuschok, Boris ^a   Pfreundschuh, Michael ^a   Breit, Rainer ^a   Hartmann, Frank ^a   Sester, Martina ^a   Gärtner, Barbara ^a   König, Jochem ^b   Murawski, Niels ^a   Held, Gerhard ^a   Zwick, Carsten ^a   Neumann, Frank ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

RAS PROTEIN;

ABDOMINAL PAIN; ADULT; AGED; ANOREXIA; ANTIGEN PRESENTING CELL; ARTICLE; CANCER GENE THERAPY; CANCER IMMUNIZATION; CANCER STAGING; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CYTOTOXIC T LYMPHOCYTE; DEPRESSION; DIARRHEA; DNA MODIFICATION; DRUG HYPERSENSITIVITY; DRUG SAFETY; EDEMA; EMBOLISM; EPSTEIN BARR VIRUS; EXPRESSION VECTOR; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; INJECTION SITE REACTION; LYMPHOBLASTOID CELL LINE; LYMPHOCYTOPENIA; MALE; NAUSEA; NEUTROPENIA; PANCREAS ADENOCARCINOMA; PHASE 1 CLINICAL TRIAL; PILOT STUDY; VOMITING;

ADENOCARCINOMA; AGED; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TRANSFORMED; CHEMOTHERAPY, ADJUVANT; CYTOKINES; FEMALE; GENES, RAS; HERPESVIRUS 4, HUMAN; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PANCREATICODUODENECTOMY; PILOT PROJECTS; T-LYMPHOCYTES; TRANSFECTION; TREATMENT OUTCOME;

HUMAN HERPESVIRUS 4;

EID: 84871190802     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2011.153     Document Type: Article

References (50)

1. Ancrile, B.B., O'Hayer, K.M., and Counter, C.M. (2008). Oncogenic ras-induced expression of cytokines: a new target of anti-cancer therapeutics. Mol. Interv. 8, 22-27.
2. Bangham, C.R., and McMichael, A.J. (1986). Specific human cytotoxic T cells recognize B-cell lines persistently infected with respiratory syncytial virus. Proc. Natl. Acad. Sci. U.S.A. 83, 9183-9187.
3. Bardelli, A., and Siena, S. (2010). Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J. Clin. Oncol. 28, 1254-1261.
4. Bettink, S.I., Werner, C., Chen. C.H., et al. (2010). Integrin-linked kinase is a central mediator in angiotensin II type 1- and chemokine receptor CXCR4 signaling in myocardial hypertrophy. Biochem. Biophys. Res. Commun. 397, 208-213.
5. Bickham, K., Goodman, K., Paludan, C., et al. (2003). Dendritic cells initiate immune control of epstein-barr virus transformation of B lymphocytes in vitro. J. Exp. Med. 198, 1653-1663.
6. Bird, A.G., McLachlan, S.M., and Britton, S. (1981). Cyclosporin A promotes spontaneous outgrowth in vitro of Epstein-Barr virus-induced B-cell lines. Nature 289, 300-301.
7. Buckwalter, M.R., and Srivastava, P.K. (2008). "It is the antigen (s), stupid" and other lessons from over a decade of vaccitherapy of human cancer. Semin. Immunol. 20, 296-300.
8. Disis, M.L., Bernhard, H., and Jaffee, E.M. (2009). Use of tumourresponsive T cells as cancer treatment. Lancet 373, 673-683.
9. Dudley, M.E., Wunderlich, J.R., Yang, J.C., et al. (2002). A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J. Immunother. 25, 243-251.
10. Emens, L.A. (2008). Cancer vaccines: on the threshold of success. Expert Opin. Emerg. Drugs 13, 295-308.
11. Finn, O.J. (2008). Cancer immunology. N. Engl. J. Med. 358, 2704-2715.
12. Fontana, R., Bregni, M., Cipponi, A., et al. (2009). Peripheral blood lymphocytes genetically modified to express the self/tumor antigen MAGE-A3 induce antitumor immune responses in cancer patients. Blood 113, 1651-1660.
13. Hodi, F.S., O'Day, S.J., McDermott, D.F., et al. (2010). Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711-723.
14. Iezzi, G., Boni, A., Degl'Innocenti, E., et al. (2006). Type 2 cytotoxic T lymphocytes modulate the activity of dendritic cells toward type 2 immune responses. J. Immunol. 177, 2131-2137.
15. Jacobs, A.D., Burris, H.A., Rivkin, S, et al. (2004). A randomized phase III study of rubitecan (ORA) vs. best choice (BC) in 409 patients with refractory pancreatic cancer. J. Clin. Oncol. 22, Abstract 4013.
16. Kantoff, P.W., Higano, C.S., Shore, N.D., et al. (2010). Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363, 411-422.
17. Kubuschok, B., Cochlovius, C., Jung, W.,et al. (2000). Genemodified spontaneous Epstein-Barr virus-transformed lymphoblastoid cell lines as autologous cancer vaccines: mutated p21 ras oncogene as a model. Cancer Gene Ther. 7, 1231-1240.
18. Kubuschok, B., Schmits, R., Hartmann, F., et al. (2002). Use of spontaneous Epstein-Barr virus-lymphoblastoid cell lines genetically modified to express tumor antigen as cancer vaccines: mutated p21 ras oncogene in pancreatic carcinoma as a model. Hum. Gene Ther. 13, 815-827.
19. Kubuschok, B., Neumann, F., Breit, R., et al. (2006). Naturally occurring T-cell response against mutated p21 ras oncoprotein in pancreatic cancer. Clin. Cancer Res. 12, 1365-1372.
20. Kurts, C., Robinson, B.W., and Knolle, P.A. (2010). Crosspriming in health and disease. Nat. Rev. Immunol. 10, 403-414.
21. Lacerda, J.F., Ladanyi, M., Louie, D.C., et al. (1996). Human Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes home preferentially to and induce selective regressions of autologous EBV-induced B cell lymphoproliferations in xenografted C.B-17 scid/scid mice. J. Exp. Med. 183, 1215-1228.
22. Martin, A., Magnusson, R.P., Kendler, D.L., et al. (1993). Endogenous antigen presentation by autoantigen-transfected Epstein-Barr virus-lymphoblastoid cells. I. Generation of human thyroid peroxidase-reactive T cells and their T cell receptor repertoire. J. Clin. Invest. 91, 1567-1574.
23. Meliff, C.J. (2008). Cancer immunotherapy by dendritic cells. Immunity 29, 372-383.
24. Miyauchi, K., Urano, E., Yoshiyama, H., and Komano, J. (2011). Cytokine signatures of transformed B cells with distinct Epstein-Barr virus latencies as a potential diagnostic tool for B cell lymphoma. Cancer Sci. 102, 1236-1241.
25. Moore, A.E., Rhoads, C.P., and Southam, C.M. (1957). Homotransplantation of human cell lines. Science 125, 158-160.
26. Moore, M.J., Goldstein, D., Hamm, J., et al. (2007). Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 25, 1960-1966.
27. Mullins, D.W., Sheasley, S.L., Ream, R.M., et al. (2003). Route of immunization with peptide-pulsed dendritic cells controls the distribution of memory and effector T cells in lymphoid tissues and determines the pattern of regional tumor control. J. Exp. Med. 198, 1023-1034.
28. Murray, R.J., Kurilla, M.G., Brooks, J.M., et al. (1992). Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies. J. Exp. Med. 176, 157-168.
29. Neoptolemos, J.P., Stocken, D.D., Friess, H., et al. (2004). A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N. Engl. J. Med. 350, 1200-1210.
30. Neoptolemos, J.P., Stocken, D.D., Bassi, C., et al. (2010). Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA 304, 1073-1081.
31. Palucka, K., Ueno, H., and Banchereau, J. (2011). Recent developments in cancer vaccines. J. Immunol. 186, 1325-1331.
32. Pecher, G., and Finn, O.J. (1996). Induction of cellular immunity in chimpanzees to human tumor-associated antigen mucin by vaccination with MUC-1 cDNA-transfected Epstein-Barr virus-immortalized autologous B cells. Proc. Natl. Acad. Sci. U.S.A. 93, 1699-1704.
33. Ribas, A. (2005). Genetically modified dendritic cells for cancer immunotherapy. Curr. Gene Ther. 5, 619-628.
34. Ribas, A., Butterfield, L.H., Hu, B., et al. (2000). Immune deviation and Fas-mediated deletion limit antitumor activity after multiple dendritic cell vaccinations in mice. Cancer Res. 60, 2218-2224.
35. Rosenberg, S.A., Yang, J.C., Schwartzentruber, D.J., et al. (1998). Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med. 4, 321-327.
36. Schirrmacher, V. (2005). Clinical trials of antitumor vaccination with an autologous tumor cell vaccine modified by virus infection: improvement of patient survival based on improved antitumor immune memory. Cancer Immunol. Immunother. 54, 587-598.
37. Schuster, S.J., Neelapu, S.S., Gause, B.L., et al. (2011). Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma. J. Clin. Oncol. 29, 2787-2794.
38. Sobin, L.H., Gospodarowicz, M.K., Wittekind, C., eds (2009). TNM Classification of Malignant Tumours (ed 7) (Wiley, Weinheim, Germany), pp 122-25.
39. Stuge, T.B., Holmes, S.P., Saharan, S., et al. (2004). Diversity and recognition efficiency of T cell responses to cancer. PLoS Med. 1, e28.
40. Sun, Q., Pollok, K.E., Burton, R.L., et al. (1999). Simultaneous ex vivo expansion of cytomegalovirus and Epstein-Barr virusspecific cytotoxic T lymphocytes using B-lymphoblastoid cell lines expressing cytomegalovirus pp65. Blood 94, 3242-3250.
41. Tacken, P.J., De Vries, I.J., Torensma, R., and Figdor, C.G. (2007). Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat. Rev. Immunol. 7, 790-802.
42. Tassi, E., Gavazzi, F., Albarello, L., et al. (2008). Carcinoembryonic antigen-specific but not antiviral CD4+ T cell immunity is impaired in pancreatic carcinoma patients. J. Immunol. 181, 6595-6603.
43. Therasse, P., Arbuck, S.G., Eisenhauer, E.A., et al. (2000). New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst. 92, 205-216.
44. Thurner, B., Roder, C., Dieckmann, D., et al. (1999). Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application. J. Immunol. Methods 223, 1-15.
45. Trotti, A., Colevas, A.D., Setser, A., et al. (2003). CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin. Radiat. Oncol. 13, 176-181.
46. von Bernstorff, W., Voss, M., Freichel, S., et al. (2001). Systemic and local immunosuppression in pancreatic cancer patients. Clin. Cancer Res. 7, 925s-932s.
47. Walter, J., Moller, P., Moldenhauer, G., et al. (1992). Local growth of a Burkitt's lymphoma versus disseminated invasive growth of the autologous EBV-immortalized lymphoblastoid cells and their somatic cell hybrids in SCID mice. Int. J. Cancer 50, 265-273.
48. Wang, R.F. (2008). CD8+ regulatory T cells, their suppressive mechanisms, and regulation in cancer. Hum. Immunol. 69, 811-814.
49. Xiong, H.Q., Varadhachary, G.R., Blais, J.C., et al. (2008). Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer. Cancer 113, 2046-2052.
50. Zinkernagel, R.M. (2003). On natural and artificial vaccinations. Annu. Rev. Immunol. 21, 515-546.